Background

The present innovation generally relates to the field of targeted delivery systems for delivering therapeutic agents to tumors, in particular to tumor cells and tumor-associated cells. The invention further relates to methods of delivering a therapeutic agent to tumor cells and tumor-associated cells for the prevention and treatment of cancer by killing tumor cells and tumor-associated cells. Specifically, the delivery systems of the present innovation are capable of delivering an increased amount of therapeutics to tumor cells and tumor associated cells as compared to other delivery systems. In particular, the delivery systems of the present innovation are capable of accumulating a higher amount of therapeutic agent in tumor cells, or in cells that contribute to tumor cell viability (